Abstract
The rapidly increasing prevalence of type 2 diabetes (T2D) is motivating an intensive search for biomarkers to identify individuals at risk for developing the disease. It has been established that both genetic and environmental factors are influential in the progression to T2D. Currently, the number of genetic loci implicated in T2D susceptibility is more than 65 and together, these factors explain only about 10% of the risk. At this time, prediction models using genetic information do not perform substantially better than models based on routine clinical measures. The search for new biomarkers must integrate new, independent factors beyond the static genome that are influenced by environmental conditions. This search must also recognize the heterogeneity of T2D and seek new biomarkers of potential subtypes and confounding conditions such as obesity. Modulation of gene expression by epigenetic modifications and the action of microRNAs are being recognized as critical processes affecting T2D risk. This review provides an update on the current state of genetic biomarkers of T2D susceptibility and examines how epigenetic modulation of some new and established diabetes susceptibility genes can identify increased risk and provide biomarkers for early detection and therapeutic monitoring.
Keywords: Diabetes, pre-diabetes, genetics, epigenetics, microRNA, GWAS, biomarker.
Current Diabetes Reviews
Title:DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes
Volume: 12 Issue: 1
Author(s): Thomas M. O’Connell and Christina A. Markunas
Affiliation:
Keywords: Diabetes, pre-diabetes, genetics, epigenetics, microRNA, GWAS, biomarker.
Abstract: The rapidly increasing prevalence of type 2 diabetes (T2D) is motivating an intensive search for biomarkers to identify individuals at risk for developing the disease. It has been established that both genetic and environmental factors are influential in the progression to T2D. Currently, the number of genetic loci implicated in T2D susceptibility is more than 65 and together, these factors explain only about 10% of the risk. At this time, prediction models using genetic information do not perform substantially better than models based on routine clinical measures. The search for new biomarkers must integrate new, independent factors beyond the static genome that are influenced by environmental conditions. This search must also recognize the heterogeneity of T2D and seek new biomarkers of potential subtypes and confounding conditions such as obesity. Modulation of gene expression by epigenetic modifications and the action of microRNAs are being recognized as critical processes affecting T2D risk. This review provides an update on the current state of genetic biomarkers of T2D susceptibility and examines how epigenetic modulation of some new and established diabetes susceptibility genes can identify increased risk and provide biomarkers for early detection and therapeutic monitoring.
Export Options
About this article
Cite this article as:
M. O’Connell Thomas and A. Markunas Christina, DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes, Current Diabetes Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573399811666150515125557
DOI https://dx.doi.org/10.2174/1573399811666150515125557 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetics Talks to Epigenetics? The Interplay Between Sequence Variants and Chromatin Structure
Current Genomics Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction
Current Diabetes Reviews Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases
Current Vascular Pharmacology Anti-Phospholipase A2 Receptor Autoantibody: A New Biomarker for Primary Membranous Nephropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Susceptibility Genes in Hypertension
Current Pharmaceutical Design Toll-like Receptors and Diabetes Complications: Recent Advances
Current Diabetes Reviews Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
Current Gene Therapy Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes
Current Vascular Pharmacology Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) Dietary Patterns and Prevention of Type 2 Diabetes: From Research to Clinical Practice; A Systematic Review
Current Diabetes Reviews Pilot Study of Eyesight Characteristics and Thickness of the Retinal Nerve Fiber and Ganglion Cell-inner Plexiform Layers in Adolescent Patients with Type one Diabetes Mellitus on an Insulin Pump
Current Pharmaceutical Design Quality of Life in Individuals with Diabetic Foot Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets A Study of Correlation between Anti-peroxidative Potential of Quercetin and Ascorbic Acid with Malondialdehyde by RP-HPLC
Current Chemical Biology Angiotensin Type 1 Receptor Blockers in Heart Failure
Current Drug Targets A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering
Current Drug Targets Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus
Vascular Disease Prevention (Discontinued)